{"transactions":[{"id":969944,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GSK plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-15T21:32:10.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":1470000,"price":19,"value":27930000.0,"ownership":{"direct":false,"nature":"By Corporation"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the \"Reporting Person\")."}],"balance_after":18245691,"source":{"system":"sec-edgar","filing":"0001999371-25-020336","document":"gsk-form4_121225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000199937125020336/gsk-form4_121225.xml","form_type":"4"}},{"id":1397002,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GSK plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2024-10-01T21:54:39.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":2791930,"price":8,"value":22335440.0,"ownership":{"direct":false,"nature":"By Corporation"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the \"Reporting Person\")."}],"balance_after":16775691,"source":{"system":"sec-edgar","filing":"0001999371-24-012789","document":"wve-form4_092724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000199937124012789/wve-form4_092724.xml","form_type":"4"}},{"id":1666814,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GSK plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2024-01-30T21:39:08.000Z","date":"2023-12-07","kind":"purchase","planned":false,"acquired":true,"shares":3300000,"price":5,"value":16500000.0,"ownership":{"direct":false,"nature":"By Corporation"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the \"Reporting Person\")."}],"balance_after":13983761,"source":{"system":"sec-edgar","filing":"0001999371-24-001192","document":"gsk-form4_120723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000199937124001192/gsk-form4_120723.xml","form_type":"4"}},{"id":2154280,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GSK PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Exchangeable Senior Notes due 2023","published_at":"2022-09-20T20:16:05.000Z","date":"2022-09-16","kind":"other","acquired":true,"reported_value":269061000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GSK plc (\"GSK\"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GSK plc (\"GSK\"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GSK plc (\"GSK\"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GSK plc (\"GSK\"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GSK plc (\"GSK\"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding."}],"balance_after":0,"derivative":{"exercise_price":29.066,"underlying":"Ordinary Shares","underlying_shares":9256882},"source":{"system":"sec-edgar","filing":"0001387131-22-009897","document":"tbph-form4_091622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713122009897/tbph-form4_091622.xml","form_type":"4"}},{"id":2154279,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GSK PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Ordinary Shares","published_at":"2022-09-20T20:16:05.000Z","date":"2022-09-16","kind":"other","acquired":false,"shares":9644807,"price":9.75,"value":94036868.25,"ownership":{"direct":false,"nature":"By Corporation"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GSK plc (\"GSK\"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding."},{"field":"kind","element":"transactionCoding","label":"F2","text":"All 9,644,807 Ordinary Shares previously held by GSK were sold back to Theravance Biopharma pursuant to a Stock Repurchase Agreement dated September 16, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GSK plc (\"GSK\"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001387131-22-009897","document":"tbph-form4_091622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713122009897/tbph-form4_091622.xml","form_type":"4"}},{"id":2641735,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Preferred Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":10055408,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":635646},"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641734,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F-2 Preferred Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":1081434,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":27345},"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641733,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-2 Preferred Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":331399,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8380},"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641732,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D-2 Preferred Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":589939,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14917},"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641731,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":513312,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12979},"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641730,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":59527,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1505},"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641729,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"purchase","acquired":true,"shares":275000,"price":18,"value":4950000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person."}],"balance_after":1007583,"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641728,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":635646,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":732583,"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641727,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":27345,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":96937,"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641726,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":8380,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":69592,"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641725,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":14917,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":61212,"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641724,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":12979,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":46295,"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2641723,"issuer":{"id":6920,"kind":"organization","name":"CVRx, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:38:14.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":1505,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":33316,"source":{"system":"sec-edgar","filing":"0001387131-21-007179","document":"cvrx-form4_070221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121007179/cvrx-form4_070221.xml","form_type":"4"}},{"id":2657648,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series AA Preferred Stock","published_at":"2021-06-23T22:14:59.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":30253189,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30253189},"source":{"system":"sec-edgar","filing":"0001387131-21-006822","document":"gsk-form4_062121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121006822/gsk-form4_062121.xml","form_type":"4"}},{"id":2657647,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-23T22:14:59.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":30253189,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":30253189,"source":{"system":"sec-edgar","filing":"0001387131-21-006822","document":"gsk-form4_062121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121006822/gsk-form4_062121.xml","form_type":"4"}},{"id":2699487,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T21:04:29.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":32005260,"price":12.25,"value":392064435.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Common stock sold pursuant to a share repurchase agreement by and between Glaxo Group Limited (\"GGL\"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the \"Issuer\") dated as of May 20, 2021."},{"field":"shares","element":"transactionShares","label":"F1","text":"Common stock sold pursuant to a share repurchase agreement by and between Glaxo Group Limited (\"GGL\"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the \"Issuer\") dated as of May 20, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Common Stock was held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001387131-21-006039","document":"inva-form4_052021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000138713121006039/inva-form4_052021.xml","form_type":"4"}},{"id":2846670,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2021-02-19T21:50:09.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":1737619,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series D Preferred Stock automatically converted into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series D Preferred Stock automatically converted into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series D Preferred Stock automatically converted into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series D Preferred Stock automatically converted into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":327852},"source":{"system":"sec-edgar","filing":"0001387131-21-002710","document":"dbtx-form4_021721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121002710/dbtx-form4_021721.xml","form_type":"4"}},{"id":2846669,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-02-19T21:50:09.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":3125000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C Preferred Stock automatically converted into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C Preferred Stock automatically converted into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C Preferred Stock automatically converted into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C Preferred Stock automatically converted into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":247324},"source":{"system":"sec-edgar","filing":"0001387131-21-002710","document":"dbtx-form4_021721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121002710/dbtx-form4_021721.xml","form_type":"4"}},{"id":2846668,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-02-19T21:50:09.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":7119850,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock automatically converted into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock automatically converted into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock automatically converted into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458487},"source":{"system":"sec-edgar","filing":"0001387131-21-002710","document":"dbtx-form4_021721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121002710/dbtx-form4_021721.xml","form_type":"4"}},{"id":2846667,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T21:50:09.000Z","date":"2021-02-17","kind":"purchase","acquired":true,"shares":150000,"price":18,"value":2700000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"GSK Equity Investments, Limited purchased 150,000 shares of common stock in connection with the issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1183663,"source":{"system":"sec-edgar","filing":"0001387131-21-002710","document":"dbtx-form4_021721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121002710/dbtx-form4_021721.xml","form_type":"4"}},{"id":2846666,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T21:50:09.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":327852,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series D Preferred Stock automatically converted into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1033663,"source":{"system":"sec-edgar","filing":"0001387131-21-002710","document":"dbtx-form4_021721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121002710/dbtx-form4_021721.xml","form_type":"4"}},{"id":2846665,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T21:50:09.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":247324,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C Preferred Stock automatically converted into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":705811,"source":{"system":"sec-edgar","filing":"0001387131-21-002710","document":"dbtx-form4_021721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121002710/dbtx-form4_021721.xml","form_type":"4"}},{"id":2846664,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T21:50:09.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":458487,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":458487,"source":{"system":"sec-edgar","filing":"0001387131-21-002710","document":"dbtx-form4_021721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713121002710/dbtx-form4_021721.xml","form_type":"4"}},{"id":3027179,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T16:04:24.000Z","date":"2020-07-15","kind":"sale","acquired":false,"shares":78,"price":19.25,"value":1501.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1910531,"source":{"system":"sec-edgar","filing":"0001387131-20-008376","document":"bcyc-form4_071420.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120008376/bcyc-form4_071420.xml","form_type":"4"}},{"id":3027178,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T16:04:24.000Z","date":"2020-07-15","kind":"sale","acquired":false,"shares":3069,"price":19.4016,"value":59543.5104,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1910609,"source":{"system":"sec-edgar","filing":"0001387131-20-008376","document":"bcyc-form4_071420.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120008376/bcyc-form4_071420.xml","form_type":"4"}},{"id":3027177,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T16:04:24.000Z","date":"2020-07-14","kind":"sale","acquired":false,"shares":1597,"price":19.274,"value":30780.578,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1913678,"source":{"system":"sec-edgar","filing":"0001387131-20-008376","document":"bcyc-form4_071420.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120008376/bcyc-form4_071420.xml","form_type":"4"}},{"id":3073468,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2020-07-31T00:56:55.000Z","date":"2020-07-24","kind":"purchase","acquired":true,"shares":1260504,"price":0.125,"value":157563.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"S.R. One, Limited acquired 1,260,504 shares of Common Stock of Genocea Biosciences, Inc (the \"Issuer\") and warrants exercisable for up to up to 1,260,504 shares of Common Stock (the \"Warrants\"), subject to anti-dilution adjustments in a private placement by the Issuer, which closed on July 24, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited acquired 1,260,504 shares of Common Stock of Genocea Biosciences, Inc (the \"Issuer\") and warrants exercisable for up to up to 1,260,504 shares of Common Stock (the \"Warrants\"), subject to anti-dilution adjustments in a private placement by the Issuer, which closed on July 24, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants are exercisable at any time prior to 5:00 pm New York City time on the expiration date, subject to a restriction on exercise if the holder, together with its attribution parties, would, after giving effect to the exercise, beneficially own more 9.99% of the Issuer's then outstanding Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"S.R. One, Limited acquired 1,260,504 shares of Common Stock of Genocea Biosciences, Inc (the \"Issuer\") and warrants exercisable for up to up to 1,260,504 shares of Common Stock (the \"Warrants\"), subject to anti-dilution adjustments in a private placement by the Issuer, which closed on July 24, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"S.R. One, Limited acquired 1,260,504 shares of Common Stock of Genocea Biosciences, Inc (the \"Issuer\") and warrants exercisable for up to up to 1,260,504 shares of Common Stock (the \"Warrants\"), subject to anti-dilution adjustments in a private placement by the Issuer, which closed on July 24, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1260504,"derivative":{"exercise_price":2.25,"expiration_date":"2024-07-24","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001387131-20-006914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006914/ownership.xml","form_type":"4"}},{"id":3073467,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-31T00:56:55.000Z","date":"2020-07-24","kind":"purchase","acquired":true,"shares":1260504,"price":2.25,"value":2836134.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited acquired 1,260,504 shares of Common Stock of Genocea Biosciences, Inc (the \"Issuer\") and warrants exercisable for up to up to 1,260,504 shares of Common Stock (the \"Warrants\"), subject to anti-dilution adjustments in a private placement by the Issuer, which closed on July 24, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":4626389,"source":{"system":"sec-edgar","filing":"0001387131-20-006914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006914/ownership.xml","form_type":"4"}},{"id":3078039,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-22T20:18:13.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":13997,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option was granted to Jill A. Carroll as director's compensation with the shares vesting with respect to 2.7778% of the shares at the end of each successive one month period following the grant date until the third anniversary of the grant date. As Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc., Ms. Carroll disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":13997,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":13997},"source":{"system":"sec-edgar","filing":"0001387131-20-006601","document":"pand-form_072120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006601/pand-form_072120.xml","form_type":"4"}},{"id":3078038,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-22T20:18:13.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":1776980,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":348469},"source":{"system":"sec-edgar","filing":"0001387131-20-006601","document":"pand-form_072120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006601/pand-form_072120.xml","form_type":"4"}},{"id":3078037,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-22T20:18:13.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":7846554,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1538724},"source":{"system":"sec-edgar","filing":"0001387131-20-006601","document":"pand-form_072120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006601/pand-form_072120.xml","form_type":"4"}},{"id":3078036,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T20:18:13.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":361111,"price":18,"value":6499998.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"S.R. One, Limited purchased 361,111 shares of Common Stock of Pandion Therapeutics, Inc. (the \"Issuer\") in connection with the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2248304,"source":{"system":"sec-edgar","filing":"0001387131-20-006601","document":"pand-form_072120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006601/pand-form_072120.xml","form_type":"4"}},{"id":3078035,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T20:18:13.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":348469,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1887193,"source":{"system":"sec-edgar","filing":"0001387131-20-006601","document":"pand-form_072120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006601/pand-form_072120.xml","form_type":"4"}},{"id":3078034,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T20:18:13.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":1538724,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 5.0994 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1538724,"source":{"system":"sec-edgar","filing":"0001387131-20-006601","document":"pand-form_072120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006601/pand-form_072120.xml","form_type":"4"}},{"id":3081920,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"grant","acquired":true,"shares":10700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option was granted to Simeon J. George as director's compensation and it vests 100% on the first anniversary of July 9, 2020, or, if earlier, on the day immediately preceding the first annual meeting of the Issuer's stockholders in 2021 at which one or more members of the Issuer's board of directors are to be elected. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a \"change in control\" of the Issuer occur (as described in the applicable award agreement) or upon the Simeon George's separation from service with the Issuer due to death or \"disability\" (as described in the applicable award agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"(continued from footnote 6) As Chief Executive Officer, President and a Member of the Board of Trustees at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, Simeon J. George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":10700,"derivative":{"exercise_price":18,"expiration_date":"2030-07-08","underlying":"Common Stock","underlying_shares":10700},"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3081919,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":6337403,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1712810},"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3081918,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":1994348,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":525499},"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3081917,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":292663,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":79090},"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3081916,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"purchase","acquired":true,"shares":833333,"price":18,"value":14999994.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"S.R. One, Limited purchased 833,333 shares of Common Stock of Nkarta, Inc. (the \"Issuer\") in connection with the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":3150732,"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3081915,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":1712810,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series B Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":2317399,"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3081914,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":525499,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":604589,"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3081913,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-17T00:13:38.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":79090,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock were convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the option of the holder and were automatically converted upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":79090,"source":{"system":"sec-edgar","filing":"0001387131-20-006467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120006467/ownership.xml","form_type":"4"}},{"id":3103344,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Exchangeable Note","published_at":"2020-06-22T21:29:13.000Z","date":"2020-06-22","kind":"sale","acquired":false,"reported_value":280336000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 22, 2020, GSK Finance No.3 plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GlaxoSmithKline plc (\"GSK\"), issued $280,336,000 of its senior notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\"). The Ordinary Shares are held directly by GSK Finance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Notes are guaranteed by GSK and exchangeable at the option of noteholders on any business day on or after September 1, 2020 for up to 9,644,792 Ordinary Shares at an initial exchange rate of 34.4044 Ordinary Shares per $1,000 principal amount of Notes, which is equivalent to an initial exchange price of approximately $29.0660. Under certain circumstances, GSK Finance may deliver cash in lieu of Ordinary Shares or a combination of Ordinary Shares and cash. The sale of the Notes resulted in $304,164,560 of gross proceeds."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Notes are guaranteed by GSK and exchangeable at the option of noteholders on any business day on or after September 1, 2020 for up to 9,644,792 Ordinary Shares at an initial exchange rate of 34.4044 Ordinary Shares per $1,000 principal amount of Notes, which is equivalent to an initial exchange price of approximately $29.0660. Under certain circumstances, GSK Finance may deliver cash in lieu of Ordinary Shares or a combination of Ordinary Shares and cash. The sale of the Notes resulted in $304,164,560 of gross proceeds."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 22, 2020, GSK Finance No.3 plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GlaxoSmithKline plc (\"GSK\"), issued $280,336,000 of its senior notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\"). The Ordinary Shares are held directly by GSK Finance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On June 22, 2020, GSK Finance No.3 plc (\"GSK Finance\"), a wholly owned indirect subsidiary of GlaxoSmithKline plc (\"GSK\"), issued $280,336,000 of its senior notes due 2023 (the \"Notes\") exchangeable into ordinary shares (\"Ordinary Shares\") of Theravance Biopharma, Inc. (\"Theravance Biopharma\"). The Ordinary Shares are held directly by GSK Finance."}],"balance_after":0,"derivative":{"exercise_price":29.066,"underlying":"Ordinary Shares","underlying_shares":9644792},"source":{"system":"sec-edgar","filing":"0001387131-20-005871","document":"tbph-form4_062220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120005871/tbph-form4_062220.xml","form_type":"4"}},{"id":3135497,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-26T20:17:25.000Z","date":"2020-05-21","kind":"purchase","acquired":true,"shares":83333,"price":60,"value":4999980.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited purchased 83,333 shares of Common Stock of Turning Point Therapeutics, Inc (the \"Issuer\") in connection with the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2253660,"source":{"system":"sec-edgar","filing":"0001387131-20-005182","document":"tptx-form4_052120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120005182/tptx-form4_052120.xml","form_type":"4"}},{"id":3139400,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-21T21:21:18.000Z","date":"2020-05-20","kind":"sale","acquired":false,"shares":4000000,"price":25.75,"value":103000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":6238244,"source":{"system":"sec-edgar","filing":"0001387131-20-005115","document":"pgny-form4_052120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713120005115/pgny-form4_052120.xml","form_type":"4"}},{"id":3384676,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-10-31T22:27:49.000Z","date":"2019-10-29","kind":"exercise","acquired":false,"shares":9821190,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer (the \"Certificate of Incorporation\"), on October 29, 2019, the shares of Series B Preferred Stock automatically converted into 9,821,190 shares of Common Stock upon the closing of the Issuer's initial public offering. Pursuant to the Certificate of Incorporation, the Series B Preferred Stock had been convertible, at the election of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer (the \"Certificate of Incorporation\"), on October 29, 2019, the shares of Series B Preferred Stock automatically converted into 9,821,190 shares of Common Stock upon the closing of the Issuer's initial public offering. Pursuant to the Certificate of Incorporation, the Series B Preferred Stock had been convertible, at the election of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer (the \"Certificate of Incorporation\"), on October 29, 2019, the shares of Series B Preferred Stock automatically converted into 9,821,190 shares of Common Stock upon the closing of the Issuer's initial public offering. Pursuant to the Certificate of Incorporation, the Series B Preferred Stock had been convertible, at the election of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9821190},"source":{"system":"sec-edgar","filing":"0001387131-19-008140","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713119008140/ownership.xml","form_type":"4"}},{"id":3384675,"issuer":{"id":4521,"kind":"organization","name":"Progyny, Inc.","symbol":"PGNY"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-31T22:27:49.000Z","date":"2019-10-29","kind":"exercise","acquired":true,"shares":9821190,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer (the \"Certificate of Incorporation\"), on October 29, 2019, the shares of Series B Preferred Stock automatically converted into 9,821,190 shares of Common Stock upon the closing of the Issuer's initial public offering. Pursuant to the Certificate of Incorporation, the Series B Preferred Stock had been convertible, at the election of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":10238244,"source":{"system":"sec-edgar","filing":"0001387131-19-008140","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713119008140/ownership.xml","form_type":"4"}},{"id":3389829,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2019-10-22T21:36:02.000Z","date":"2019-10-18","kind":"purchase","acquired":true,"shares":357142,"price":28,"value":9999976.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited purchased 357,142 shares of Common Stock of Principia Biopharma Inc. (the \"Issuer\") in connection with the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2982855,"source":{"system":"sec-edgar","filing":"0001387131-19-007820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713119007820/ownership.xml","form_type":"4"}},{"id":3416395,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-12T20:18:46.000Z","date":"2019-09-10","kind":"purchase","acquired":true,"shares":177777,"price":45,"value":7999965.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited purchased 177,777 shares of Common Stock of Turning Point Therapeutics, Inc (the \"Issuer\") in connection with the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2170327,"source":{"system":"sec-edgar","filing":"0001387131-19-006905","document":"glaxosmithkline.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000138713119006905/glaxosmithkline.xml","form_type":"4"}},{"id":3456875,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2019-07-24T20:01:08.000Z","date":"2019-07-22","kind":"exercise","acquired":false,"shares":12500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 22, 2019 upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock converted into Common Stock on a seven-for-one basis without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the IPO. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 22, 2019 upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock converted into Common Stock on a seven-for-one basis without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the IPO. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 22, 2019 upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock converted into Common Stock on a seven-for-one basis without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the IPO. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1785714},"source":{"system":"sec-edgar","filing":"0001140361-19-013355","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000114036119013355/form4.xml","form_type":"4"}},{"id":3456874,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-07-24T20:01:08.000Z","date":"2019-07-22","kind":"exercise","acquired":true,"shares":1785714,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 22, 2019 upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock converted into Common Stock on a seven-for-one basis without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the IPO. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1785714,"source":{"system":"sec-edgar","filing":"0001140361-19-013355","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000114036119013355/form4.xml","form_type":"4"}},{"id":3471717,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B preferred stock","published_at":"2019-07-02T20:13:23.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":830489,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in its initial public offering (the 'IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date.."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":830489},"source":{"system":"sec-edgar","filing":"0000903423-19-000271","document":"glaxo.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000271/glaxo.xml","form_type":"4"}},{"id":3471716,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A preferred stock","published_at":"2019-07-02T20:13:23.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":1469950,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in its initial public offering (the 'IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date.."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in its initial public offering (the 'IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date.."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in its initial public offering (the 'IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date.."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1469950},"source":{"system":"sec-edgar","filing":"0000903423-19-000271","document":"glaxo.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000271/glaxo.xml","form_type":"4"}},{"id":3471715,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T20:13:23.000Z","date":"2019-07-01","kind":"purchase","acquired":true,"shares":333333,"price":15,"value":4999995.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited acquired 333,333 common shares of the Issuer in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2633772,"source":{"system":"sec-edgar","filing":"0000903423-19-000271","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000271/glaxo.xml","form_type":"4"}},{"id":3471714,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T20:13:23.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":830489,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2300439,"source":{"system":"sec-edgar","filing":"0000903423-19-000271","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000271/glaxo.xml","form_type":"4"}},{"id":3471713,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T20:13:23.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":1469950,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series A Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in its initial public offering (the 'IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date.."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1469950,"source":{"system":"sec-edgar","filing":"0000903423-19-000271","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000271/glaxo.xml","form_type":"4"}},{"id":3478172,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T14:46:51.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":1857142,"price":3.5,"value":6499997.0,"ownership":{"direct":false,"nature":"See Footenote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited acquired 1,857,142 shares of Common Stock of Genocea Biosciences, Inc. (the \"Issuer\") in connection with the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":3365884,"source":{"system":"sec-edgar","filing":"0000903423-19-000257","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000257/glaxo.xml","form_type":"4"}},{"id":3488295,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option","published_at":"2019-06-17T18:57:53.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was granted to Simeon George as director's compensation and vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of Simeon George on each vesting date.  As President of S. R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The stock option was granted to Simeon George as director's compensation and vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of Simeon George on each vesting date.  As President of S. R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":10240,"derivative":{"exercise_price":31.77,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0000903423-19-000249","document":"prnb.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000249/prnb.xml","form_type":"4"}},{"id":3507689,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B1 Preferred Shares","published_at":"2019-05-30T21:47:38.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":445323,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":636366},"source":{"system":"sec-edgar","filing":"0000903423-19-000235","document":"glaxo.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000235/glaxo.xml","form_type":"4"}},{"id":3507688,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2019-05-30T21:47:38.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":625049,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":893195},"source":{"system":"sec-edgar","filing":"0000903423-19-000235","document":"glaxo.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000235/glaxo.xml","form_type":"4"}},{"id":3507687,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:47:38.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":385714,"price":14,"value":5399996.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited acquired 385,714 Common Stock of Bicycle Therapeutics Limited (the \"Issuer\") in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1915275,"source":{"system":"sec-edgar","filing":"0000903423-19-000235","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000235/glaxo.xml","form_type":"4"}},{"id":3507686,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:47:38.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":636366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1529561,"source":{"system":"sec-edgar","filing":"0000903423-19-000235","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000235/glaxo.xml","form_type":"4"}},{"id":3507685,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:47:38.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":893195,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":893195,"source":{"system":"sec-edgar","filing":"0000903423-19-000235","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000235/glaxo.xml","form_type":"4"}},{"id":3550334,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-04-24T23:28:07.000Z","date":"2019-04-22","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option was granted to Simeon George as director's compensation and will become fully vested on the date of the company's 2020 annual meeting of stockholders, subject to vesting acceleration upon a change in control of the company, and subject to the continuing service of Simeon George on each vesting date. As a Vice President of S.R. One, limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":15000,"derivative":{"exercise_price":27.06,"expiration_date":"2029-04-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000903423-19-000197","document":"glaxo.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000197/glaxo.xml","form_type":"4"}},{"id":3550333,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2019-04-24T23:28:07.000Z","date":"2019-04-22","kind":"exercise","acquired":false,"shares":2105259,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":546820},"source":{"system":"sec-edgar","filing":"0000903423-19-000197","document":"glaxo.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000197/glaxo.xml","form_type":"4"}},{"id":3550332,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-04-24T23:28:07.000Z","date":"2019-04-22","kind":"exercise","acquired":false,"shares":4314809,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1120730},"source":{"system":"sec-edgar","filing":"0000903423-19-000197","document":"glaxo.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000197/glaxo.xml","form_type":"4"}},{"id":3550331,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T23:28:07.000Z","date":"2019-04-22","kind":"purchase","acquired":true,"shares":325000,"price":18,"value":5850000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"S.R. One, Limited acquired 325,000 Common Stock of the Issuer in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1992550,"source":{"system":"sec-edgar","filing":"0000903423-19-000197","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000197/glaxo.xml","form_type":"4"}},{"id":3550330,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T23:28:07.000Z","date":"2019-04-22","kind":"exercise","acquired":true,"shares":546820,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1667550,"source":{"system":"sec-edgar","filing":"0000903423-19-000197","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000197/glaxo.xml","form_type":"4"}},{"id":3550329,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T23:28:07.000Z","date":"2019-04-22","kind":"exercise","acquired":true,"shares":1120730,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Preferred Stock and Series D Preferred Stock were converted into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1120730,"source":{"system":"sec-edgar","filing":"0000903423-19-000197","document":"glaxo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000197/glaxo.xml","form_type":"4"}},{"id":3695649,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-01-15T21:57:57.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":20475,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was granted to Simeon George as director's compensation and vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of Simeon George on each vesting date. As a Vice President of S. R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The stock option was granted to Simeon George as director's compensation and vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of Simeon George on each vesting date. As a Vice President of S. R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc."}],"balance_after":20475,"derivative":{"exercise_price":17,"expiration_date":"2028-09-12","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0000903423-19-000029","document":"prnb.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342319000029/prnb.xml","form_type":"4"}},{"id":3787625,"issuer":{"id":122928,"kind":"organization","name":"ChemoCentryx, Inc.","symbol":"CCXI"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% holder"}}],"security":"Common Stock","published_at":"2018-10-18T21:03:29.000Z","date":"2018-10-16","kind":"sale","acquired":false,"shares":7343492,"price":11.69,"value":85845421.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock were held of record by Glaxo Group Limited, which is an indirect wholly-owned subsidiary of Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares of Common Stock were held of record by Glaxo Group Limited, which is an indirect wholly-owned subsidiary of Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000903423-18-000564","document":"chemo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000564/chemo.xml","form_type":"4"}},{"id":3810876,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":1521895,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":167537},"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810875,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Preferred Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":4942070,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":544047},"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810874,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":2367424,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":260617},"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810873,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":2840909,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":312741},"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810872,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":9726783,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1070771},"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810871,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"purchase","acquired":true,"shares":270000,"price":17,"value":4590000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited acquired 270,000 Common Stock of the Issuer in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2625713,"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810870,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":167537,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2355713,"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810869,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":544047,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2188176,"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810868,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":260617,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1644129,"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810867,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":312741,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1383512,"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3810866,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T21:18:27.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":1070771,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1070771,"source":{"system":"sec-edgar","filing":"0000903423-18-000516","document":"prnb.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000516/prnb.xml","form_type":"4"}},{"id":3856998,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% holder"}}],"security":"Series D Preferred Stock","published_at":"2018-08-01T22:32:30.000Z","date":"2018-07-30","kind":"exercise","acquired":false,"shares":344853,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series D Preferred Stock converted automatically into Common Stock on an approximately 0.0594 -for-one basis upon closing of the Issuer's initial public offering. The Series D Preferred Stock had been convertible at any time at the holder's election and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series D Preferred Stock converted automatically into Common Stock on an approximately 0.0594 -for-one basis upon closing of the Issuer's initial public offering. The Series D Preferred Stock had been convertible at any time at the holder's election and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series D Preferred Stock converted automatically into Common Stock on an approximately 0.0594 -for-one basis upon closing of the Issuer's initial public offering. The Series D Preferred Stock had been convertible at any time at the holder's election and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":336541},"source":{"system":"sec-edgar","filing":"0000903423-18-000416","document":"translate.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000416/translate.xml","form_type":"4"}},{"id":3856997,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% holder"}}],"security":"Series C-1 Preferred Stock","published_at":"2018-08-01T22:32:30.000Z","date":"2018-07-30","kind":"exercise","acquired":false,"shares":4765248,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C-1 Preferred Stock converted automatically into Common Stock on an approximately 0.0706-for-one basis upon closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had been convertible at any time at the holder's election and had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C-1 Preferred Stock converted automatically into Common Stock on an approximately 0.0706-for-one basis upon closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had been convertible at any time at the holder's election and had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C-1 Preferred Stock converted automatically into Common Stock on an approximately 0.0706-for-one basis upon closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had been convertible at any time at the holder's election and had no expiration date"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":118570},"source":{"system":"sec-edgar","filing":"0000903423-18-000416","document":"translate.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000416/translate.xml","form_type":"4"}},{"id":3856996,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% holder"}}],"security":"Common Stock","published_at":"2018-08-01T22:32:30.000Z","date":"2018-07-30","kind":"purchase","acquired":true,"shares":148818,"price":11,"value":1636998.0,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 30, 2018, Glaxo Group Limited acquired 148,818 common shares of the Issuer (\"Common Stock\") at a price of $11.00 per share in connection with the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 30, 2018, Glaxo Group Limited acquired 148,818 common shares of the Issuer (\"Common Stock\") at a price of $11.00 per share in connection with the Issuer's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,493 shares of Common Stock issuable upon exercise of Series D Warrants. The Series D Warrants are currently exercisable, with an expiration date of December 31, 2026 and an exercise price of $0.01 per share. The exercise price may be paid in cash or through net share settlement at the option of the warrantholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":624422,"source":{"system":"sec-edgar","filing":"0000903423-18-000416","document":"translate.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000416/translate.xml","form_type":"4"}},{"id":3856995,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% holder"}}],"security":"Common Stock","published_at":"2018-08-01T22:32:30.000Z","date":"2018-07-30","kind":"exercise","acquired":true,"shares":118570,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series D Preferred Stock converted automatically into Common Stock on an approximately 0.0594 -for-one basis upon closing of the Issuer's initial public offering. The Series D Preferred Stock had been convertible at any time at the holder's election and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,493 shares of Common Stock issuable upon exercise of Series D Warrants. The Series D Warrants are currently exercisable, with an expiration date of December 31, 2026 and an exercise price of $0.01 per share. The exercise price may be paid in cash or through net share settlement at the option of the warrantholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":475604,"source":{"system":"sec-edgar","filing":"0000903423-18-000416","document":"translate.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000416/translate.xml","form_type":"4"}},{"id":3856994,"issuer":{"id":145051,"kind":"organization","name":"Liquidia Technologies Inc","symbol":"LQDA"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% holder"}}],"security":"Common Stock","published_at":"2018-08-01T22:32:30.000Z","date":"2018-07-30","kind":"exercise","acquired":true,"shares":336541,"ownership":{"direct":false,"nature":"See explanation of responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C-1 Preferred Stock converted automatically into Common Stock on an approximately 0.0706-for-one basis upon closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had been convertible at any time at the holder's election and had no expiration date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,493 shares of Common Stock issuable upon exercise of Series D Warrants. The Series D Warrants are currently exercisable, with an expiration date of December 31, 2026 and an exercise price of $0.01 per share. The exercise price may be paid in cash or through net share settlement at the option of the warrantholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":475604,"source":{"system":"sec-edgar","filing":"0000903423-18-000416","document":"translate.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000416/translate.xml","form_type":"4"}},{"id":3866507,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-17T21:01:46.000Z","date":"2018-07-17","kind":"purchase","acquired":true,"shares":80000,"price":12.5,"value":1000000.0,"ownership":{"direct":false,"nature":"By S.R. One, Limited"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"S.R. One, Limited acquired 80,000 common shares of the Issuer in connection with the Issuer's offering. Shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (Reporting Person)."}],"balance_after":1934006,"source":{"system":"sec-edgar","filing":"0000903423-18-000400","document":"glaxo-spero.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000400/glaxo-spero.xml","form_type":"4"}},{"id":3875883,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-07-03T21:59:39.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":2525253,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":454550},"source":{"system":"sec-edgar","filing":"0000903423-18-000373","document":"translate.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000373/translate.xml","form_type":"4"}},{"id":3875882,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-03T21:59:39.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":7222797,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1300116},"source":{"system":"sec-edgar","filing":"0000903423-18-000373","document":"translate.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000373/translate.xml","form_type":"4"}},{"id":3875881,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-07-03T21:59:39.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":9300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"S.R. One, Limited acquired 269,230 Common Stock of the Issuer in connection with the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1674016},"source":{"system":"sec-edgar","filing":"0000903423-18-000373","document":"translate.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000373/translate.xml","form_type":"4"}},{"id":3875880,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T21:59:39.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":269230,"price":13,"value":3499990.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"S.R. One, Limited acquired 269,230 Common Stock of the Issuer in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":3697912,"source":{"system":"sec-edgar","filing":"0000903423-18-000373","document":"translate.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000373/translate.xml","form_type":"4"}},{"id":3875879,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T21:59:39.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":454550,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":3428682,"source":{"system":"sec-edgar","filing":"0000903423-18-000373","document":"translate.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000373/translate.xml","form_type":"4"}},{"id":3875878,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T21:59:39.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1300116,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":2974132,"source":{"system":"sec-edgar","filing":"0000903423-18-000373","document":"translate.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000373/translate.xml","form_type":"4"}},{"id":3875877,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2913,"kind":"organization","name":"GSK plc","position":1,"cik":"0001131399","reported_name":"GLAXOSMITHKLINE PLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T21:59:39.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1674016,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the \"Reporting Person\")."}],"balance_after":1674016,"source":{"system":"sec-edgar","filing":"0000903423-18-000373","document":"translate.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1131399/000090342318000373/translate.xml","form_type":"4"}}],"next_cursor":"2018-07-03T21:59:39.000000Z,3875877"}